RE:RE:stock price looks terribleThere is no evidence that there is or isn't a "bidding war". Pharma do not just start throwing cash at biotechs, it may look like that when an announcement gets made but many months have gone into that process before it happens. So maybe several are taking a look, maybe one, maybe no bites yet, who knows?
Here is an interesting read from an industry insider on how the process might be working for Antibe.
https://c.ymcdn.com/sites/www.michbio.org/resource/resmgr/BioToolBox_-_Commercialization/Bio_Pharma_Partnering.pdf Her take. Big Pharma's may look at 500 opportunities and whittle this down through a series of steps to 20 fullscale DDs which ends in 2-3 signed agreements. A process that she puts at 15-21 months. Thats the mountain Antibe is trying to climb, thats part of the risk profile, thats one reason the SP is not skyrocketing.
This board needs a dose of realism. Things won't just fall into Antibe's managements laps just because they have this great trial data. It certainly allows them to be taken seriously though.There is still a very long commercial and clinical path to follow and the SP will continue to reflect the difficulties in that.
Any valuation you might have may never happen and if it does it will only be realised fully towards the end of this long process. In the meantime the SP could drift anywhere I'm making no predictions up,down or sideways. News flow will be slow and meaningful SP movements will happen on meaningful news.
It may be a very negative approach but a bit of realism stops you wondering so much about the day-to-day SP moves (It doesnt stop it hurting though).